Push Admin

India's approval of homegrown vaccine criticized over lack of data

Article (news)

Krishna N. Das, Reuters

<div class="embed-wrap"><figure data-feedback="fb:likes,fb:comments"><img src="http://sa.kapamilya.com/absnews/abscbnnews/media/2021/reuters/01/04/vaccine.jpg"/><figcaption>A medic fills a syringe with COVAXIN, an Indian government-backed experimental COVID-19 vaccine, before administering it to a health worker during its trials, at the Gujarat Medical Education and Research Society in Ahmedabad, India, November 26, 2020. Amit Dave, Reuters/file</figcaption></figure></div>NEW DELHI - India on Sunday granted emergency approval to Bharat Biotech&#x27;s COVAXIN but faced questions from industry experts and opposition lawmakers after taking the step without publishing efficacy data for the homegrown coronavirus vaccine.The news, announced by the drugs controller general of India (DCGI), was hailed by Prime Minister Narendra Modi and his ministers as a success in the country&#x27;s self-reliance push.The government also approved the use of a vaccine developed by AstraZeneca and Oxford University which will be the lead vaccine in India&#x27;s immunization program.COVAXIN was jointly developed with a government institute and means India joins a small list of countries to have approved their own coronavirus vaccines.<ul class="op-related-articles">	<li><a href="https://news.abs-cbn.com/overseas/01/02/21/indias-drugs-experts-approve-astrazeneca-local-covid-vaccines">India&#x27;s drugs experts approve AstraZeneca, local COVID vaccines</a></li>	<li><a href="https://news.abs-cbn.com/overseas/01/03/21/timeline-indias-coronavirus-vaccine-approved-by-drugs-experts">TIMELINE: India&#x27;s coronavirus vaccine approved by drugs experts</a></li></ul>Bharat Biotech has partnered with drug developer Ocugen Inc to co-develop it for the U.S. market, and Brazil has signed non-binding letters of intent to buy the shot.The company has said it is in discussions with more than 10 countries about COVAXIN.&quot;Our goal is to provide global access to populations that need it the most,&quot; Bharat Biotech Chairman Krishna Ella said in a statement.&quot;COVAXIN has generated excellent safety data with robust immune responses to multiple viral proteins that persist.&quot;Neither the company nor India&#x27;s Central Drugs Standards Control Organization would reveal its efficacy results. A source with knowledge of the matter told Reuters its effectiveness could be more than 60% with two doses.China also did not publish detailed efficacy data for a vaccine it authorized on Thursday but its developer has shared interim data.&quot;On what basis was this approval given when Bharat Biotech has NOT shown enough data proving safety &amp; efficacy?&quot; transparency activist Saket Gokhale asked on Twitter.Gokhale has filed a request under India&#x27;s right-to-information law asking the government for safety and other data for the two vaccines approved on Sunday.Serum Institute of India (SII), the local maker of the AstraZeneca shot that will be branded COVISHIELD in the country, also took a dig at the Bharat Biotech vaccine.&quot;Until we get the efficacy result, how do we know that anything works?&quot; SII Chief Executive Adar Poonawalla told Reuters.A government scientist said in November COVAXIN might be approved in February or March. It is now likely to be rolled out much earlier following the approval on Sunday.Opposition lawmakers and former ministers on Sunday questioned the lack of transparency in approving it.&quot;Approval was premature and could be dangerous,&quot; said opposition lawmaker and former minister Shashi Tharoor.&quot;Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime.&quot;Vardhan urged Indians to trust that &quot;stringent protocols&quot; had been followed for the two approved vaccines.In the largest such trial in India, Bharat Biotech said it had recruited 23,000 volunteers out of a target of 26,000 for an ongoing Phase III trial of COVAXIN which began in November.<figure class="op-interactive"><iframe height="315" src="https://www.youtube.com/embed/l9VChW6FJMk?enablejsapi=1" width="560"></iframe></figure><div class="iwantbar">Watch more in <a href="//www.iwantv.com.ph/">iWantv</a> or <a href="//tfc.tv/">TFC.tv</a></div>

India on Sunday granted emergency approval to Bharat Biotech's COVAXIN but faced questions from industry experts and opposition lawmakers after taking the step without publishing efficacy data for the homegrown coronavirus vaccine.

India on Sunday granted emergency approval to Bharat Biotech's COVAXIN but faced questions from industry experts and opposition lawmakers after taking the step without publishing efficacy data for the homegrown coronavirus vaccine.

India's approval of homegrown vaccine criticized over lack of data

News

Entertainment

Lifestyle

Sports

Metro.Style

More

Sudoku

Word of the Day

Lotto

Horoscope

Overseas

India's approval of homegrown vaccine criticized over lack of data

Krishna N. Das,

Reuters

Published January 04, 2021 06:52 AM PHT

Read More:

ANC

India

India COVID-19

Covaxin

Bharat Biotech

India COVID-19 vaccine

COVID-19

coronavirus

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

AI Policy

Terms of Service

Advertise with Us

© 2026 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2026 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2026 ABS-CBN Corporation. All Rights Reserved.